Showing results (1-10 of 344) with videos related to
Sort By:
Pageof 35
Nihon Rinsho. Japanese Journal of Clinical Medicine|April 24, 2002
[The current status of structured treatment interruption]Hirotomo Nakata, Hiroaki MitsuyaExpert Opinion on Emerging Drugs|April 27, 2012
CCR5 inhibitors: emergence, success, and challengesKenji Maeda, Debananda Das, Hirotomo Nakata, et al.Current Opinion in Pharmacology|September 8, 2004
The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infectionKenji Maeda, Hirotomo Nakata, Hiromi Ogata, et al.Antiviral Therapy|October 29, 2013
Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001Kenji Maeda, Darshan V Desai, Manabu Aoki, et al.Antimicrobial Agents and Chemotherapy|April 2, 2008
Potent synergistic anti-human immunodeficiency virus (HIV) effects using combinations of the CCR5 inhibitor aplaviroc with other anti-HIV drugsHirotomo Nakata, Seth M Steinberg, Yasuhiro Koh, et al.Journal of Virology|February 1, 2005
Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse modelHirotomo Nakata, Kenji Maeda, Toshikazu Miyakawa, et al.Antiviral Therapy|June 3, 2010
Effects of CC chemokine receptor 5 (CCR5) inhibitors on the dynamics of CCR5 and CC-chemokine-CCR5 interactionsHirotomo Nakata, Michael Kruhlak, Wakako Kamata, et al.Antimicrobial Agents and Chemotherapy|October 29, 2008
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitroYasuhiro Koh, Debananda Das, Sofiya Leschenko, et al.Antimicrobial Agents and Chemotherapy|June 24, 2009
Potent activity of a nucleoside reverse transcriptase inhibitor, 4'-ethynyl-2-fluoro-2'-deoxyadenosine, against human immunodeficiency virus type 1 infection in a model using human peripheral blood mononuclear cell-transplanted NOD/SCID Janus kinase 3 knockout miceShinichiro Hattori, Kazuhiko Ide, Hirotomo Nakata, et al.International Journal of Hematology|March 17, 2016
Successful treatment of TAFRO syndrome, a variant type of multicentric Castleman disease with thrombotic microangiopathy, with anti-IL-6 receptor antibody and steroidsShiho Fujiwara, Hiromi Mochinaga, Hirotomo Nakata, et al.Pageof 35